Second Sight Medical Products, Inc., together with its subsidiaries, develops, manufactures, and markets prosthetic devices to restore functional vision of blind individuals in the United States, Canada, Europe, the Middle East, and Asia. It offers Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa. The company was formerly known as Second Sight LLC. and changed its name to Second Sight Medical Products, Inc. Second Sight Medical Products, Inc. was founded in 1998 and is headquartered in Sylmar, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EYES
CUSIPN/A
Phone818-833-5000
Debt
Debt-to-Equity RatioN/A
Current Ratio1.75
Quick Ratio1.24
Price-To-Earnings
Trailing P/E Ratio-2.59
Forward P/E Ratio-2.64
P/E GrowthN/A
Sales & Book Value
Annual Sales$7.96 million
Price / Sales12.89
Cash FlowN/A
Price / CashN/A
Book Value$0.14 per share
Price / Book10.93
Profitability
EPS (Most Recent Fiscal Year)($0.59)
Net Income$-28,510,000.00
Net Margins-418.82%
Return on Equity-432.45%
Return on Assets-232.22%
Miscellaneous
Employees112
Outstanding Shares67,070,000
Market Cap$107.99 million
Second Sight Medical Products (NASDAQ:EYES) Frequently Asked Questions
What is Second Sight Medical Products' stock symbol?
Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."
How were Second Sight Medical Products' earnings last quarter?
Second Sight Medical Products Inc (NASDAQ:EYES) issued its quarterly earnings results on Tuesday, August, 7th. The medical device company reported ($0.12) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.14) by $0.02. The medical device company earned $1.91 million during the quarter, compared to the consensus estimate of $2.21 million. Second Sight Medical Products had a negative net margin of 418.82% and a negative return on equity of 432.45%. View Second Sight Medical Products' Earnings History.
When is Second Sight Medical Products' next earnings date?
What price target have analysts set for EYES?
1 analysts have issued 1 year price objectives for Second Sight Medical Products' stock. Their predictions range from $5.00 to $5.00. On average, they expect Second Sight Medical Products' stock price to reach $5.00 in the next year. This suggests a possible upside of 226.8% from the stock's current price. View Analyst Price Targets for Second Sight Medical Products.
What is the consensus analysts' recommendation for Second Sight Medical Products?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Second Sight Medical Products in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Second Sight Medical Products.
Who are some of Second Sight Medical Products' key competitors?
Some companies that are related to Second Sight Medical Products include electroCore (ECOR), BioLife Solutions (BLFS), Rockwell Medical (RMTI), Vision Sciences (CGNT), Helius Medical Technologies (HSDT), Fonar (FONR), Semler Scientific (SMLR), Zynex Inc. common stock (ZYXI), IRIDEX (IRIX), BioSig Technologies (BSGM), Edap Tms (EDAP), Viveve Medical (VIVE), Soleno Therapeutics (SLNO), Stereotaxis (STXS) and Digirad (DRAD).
Who are Second Sight Medical Products' key executives?
Second Sight Medical Products' management team includes the folowing people:
- Mr. Stephen D. Okland Jr., Chief Commercial Officer (Age 54)
- Mr. Jonathan Will McGuire, Chief Exec. Officer, Pres and Director (Age 55)
- Gunnar Bjorg, Founder
- Mr. John T. Blake, CFO & Corp. Sec. (Age 42)
When did Second Sight Medical Products IPO?
(EYES) raised $32 million in an IPO on Wednesday, November 19th 2014. The company issued 3,500,000 shares at $9.00 per share. MDB Capital Group, LLC acted as the underwriter for the IPO.
Has Second Sight Medical Products been receiving favorable news coverage?
News articles about EYES stock have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Second Sight Medical Products earned a news impact score of 0.24 on Accern's scale. They also gave media coverage about the medical device company an impact score of 48.16 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View Recent Headlines for Second Sight Medical Products.
How do I buy shares of Second Sight Medical Products?
Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Second Sight Medical Products' stock price today?
One share of EYES stock can currently be purchased for approximately $1.53.
How big of a company is Second Sight Medical Products?
Second Sight Medical Products has a market capitalization of $107.99 million and generates $7.96 million in revenue each year. The medical device company earns $-28,510,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. Second Sight Medical Products employs 112 workers across the globe.
How can I contact Second Sight Medical Products?
Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected]
MarketBeat Community Rating for Second Sight Medical Products (NASDAQ EYES)
MarketBeat's community ratings are surveys of what our community members think about Second Sight Medical Products and other stocks. Vote "Outperform" if you believe EYES will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYES will underperform the S&P 500 over the long term. You may vote once every thirty days.
